Last reviewed · How we verify
Infliximab Adalimumab y Golimumab
These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases.
These are TNF-alpha inhibitors that block tumor necrosis factor-alpha, a key inflammatory cytokine driving immune-mediated diseases. Used for Rheumatoid arthritis, Crohn's disease, Ulcerative colitis.
At a glance
| Generic name | Infliximab Adalimumab y Golimumab |
|---|---|
| Sponsor | Fundación de Investigación Biomédica - Hospital Universitario de La Princesa |
| Drug class | TNF-alpha inhibitor |
| Target | TNF-alpha (Tumor Necrosis Factor-alpha) |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Infliximab, adalimumab, and golimumab are monoclonal antibodies or fusion proteins that bind to and neutralize TNF-alpha, preventing its interaction with TNF receptors on immune cells. This reduces inflammatory signaling and immune activation in conditions driven by excessive TNF-alpha production, such as rheumatoid arthritis, inflammatory bowel disease, and psoriasis.
Approved indications
- Rheumatoid arthritis
- Crohn's disease
- Ulcerative colitis
- Ankylosing spondylitis
- Psoriatic arthritis
- Psoriasis
- Juvenile idiopathic arthritis
Common side effects
- Infections (including serious infections)
- Tuberculosis reactivation
- Injection site reactions
- Headache
- Upper respiratory tract infections
- Infusion reactions
Key clinical trials
- Effect of Tofacitinib on Coagulation and Platelet Function, and Its Role in Thromboembolic Events (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |